• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system

September 6, 2017 By Sarah Faulkner

LumicellLumicell said today that it is launching clinical studies in breast cancer and prostate cancer with its Lum image-guided cancer surgery system.

The breast cancer trial is a pivotal study following an initial training period with surgeons, the Wellesley, Mass.-based company reported, and the prostate cancer study is a first for Lumicell and its technology.

The Lum system has a drug, device and decision software component that work together, in real-time, to guide cancer surgeons in the detection and removal of cancer cells during surgery. With the start of these two trials, the Lum system is being assessed in five solid tumor indications.

“We are excited to initiate these new studies with the Lum system, which we have designed to detect and illuminate tumor cells at the invasive front of the tumor micro-environment where macrophages and other immune cells interact with cancer cells,” chief medical officer Dr. Felix Geissler said in prepared remarks. “By enabling surgeons to clearly see cancer cells in real time during surgery, we have the opportunity to avoid leaving cancer cells behind and reduce the need for repeat surgeries. We look forward to providing further clinical updates on our progress with the Lum system later this year.”

The breast cancer and prostate cancer trials are supported by clinical feasbility data that the company touted earlier last year, showing that the Lum system achieved 100% detection of residual cancer. Lumicell is expecting to report additional clinical data in breast cancer later this year, the company said.

“We are moving our clinical program forward with strong momentum, as the Lum system is now being clinically evaluated in five cancer indications in more than 10 medical centers across the U.S.,” CEO Kelly Londy added. “We aim to set a new standard with our system in the field of image-guided cancer surgery, providing surgeons at any cancer facility with immediate visual feedback to detect tumor tissue beyond the margin of the specimen and opening up the potential to improve surgical outcomes for a broad range of cancer patients.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Surgical Tagged With: Lumicell

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS